论文部分内容阅读
目的 探讨顺铂联合乌司他丁处理胃癌细胞BGC-823后,观察细胞增殖率和细胞周期相关蛋白的变化.方法 通过体外培养胃癌细胞BGC -823.实验分为四组:对照组、顺铂化疗组、乌司他丁组以及顺铂+乌司他丁组.MTT法检测BGC-823细胞增殖率,观察顺铂及乌司他丁对胃癌细胞系增殖率的影响.Western Blot法检测胃癌细胞中细胞周期相关蛋白 Cyclin G1和 MEDF2D 的表达,RT -PCR法检测细胞中Cyclin G1的表达水平.结果 细胞增殖率结果表明:与对照组相比,顺铂组、乌司他丁组和顺铂+乌司他丁组的细胞增殖率明显降低,有显著的统计学意义 (P <0.01);与顺铂组和乌司他丁组相比,顺铂+乌司他丁组的细胞增殖率明显降低,有统计学意义 (P <0.01).Western Blot 结果显示:与对照组相比,顺铂组和乌司他丁组的 Cyclin G1和 MEDF2D 蛋白降低 (P <0.05),顺铂 +乌司他丁组的Cyclin G1和MEDF2D蛋白亦明显降低,有显著的统计学意义 (P<0.01);与顺铂组相比,顺铂+乌司他丁组的Cyclin G1和MEDF2D蛋白明显降低,有统计学意义 (P <0.01).RT -PCR 结果表明:与对照组相比,顺铂组和乌司他丁组的Cyclin G1的mRNA水平明显降低;与顺铂组和乌司他丁组相比,顺铂 +乌司他丁组的Cyclin G1的mRNA水平显著降低 (P<0.01).结论 乌司他丁能降低经顺铂化疗患者的胃癌细胞BGC-823的增殖率,这可能是通过降低细胞周期相关蛋白Cyclin G1和MEDF2D的表达所致.“,”Objective To study the changes of the proliferation and Cyclin protein after the managemeng of the gastric cancer cell BGC-823 treated by the Cisplatin combined with Ulinastatin. Methods The gastric cancer cell BGC-823 was cultured in vitro and divided into four groups: the control group, Cisplatin group, Ulinastatin group and Cisplatin+Ulinastatin group. The gastric cancer cell and the proliferation were detected by MTT; The cyclin protein of Cyclin G1 and MEDF2D was detected by Western Blot and the level of miRNA Cyclin G1 was detected by RT-PCT. Results MTT showed that compared with control group, the pro-liferation rate was obviously decreased in Cisplatin group, Ulinastatin group and Cisplatin+ Ulinastatin group. There was significant difference (P<0.01). Compared with Cisplatin group and Ulinastatin group, the proliferation rate was obviously decreased in Cispl-atin+ Ulinastatin group. There was statiscally difference (P<0.01). Western Blot showed that compared with the control group, the protein of Cyclin G1 and MEDF2D decreased in Cisplatin group and Ulinastatin group (P<0.05), and in Cisplatin+ Ulinastatin group the protein also obviously decreased (P<0.01). Compared with Cisplatin group and Ulinastatin group, the levels of Cyclin G1 and MEDF2D were significantly decreased (P<0.01). RT-PCR results showed that compared with the control group, the level of miRNA Cyclin G1 was decreased in Cisplatin group, Ulinastatin group and Cisplatin+ Ulinastatin group. Compared with Cisplatin group and Ulinastatin group, the level of miRNA Cyclin G1 was decreased in Cisplatin+ Ulinastatin group (P<0.05). Conclusion Ulinastatin can decrease the proliferation of gastric cancer cell BGC-823 and is relate to the decreasing the cyclin protein of Cyclin G1 and MEDF2D.